HemaFlo Therapeutics Team
President and CEO
Mike has a track record of building and leading multidisciplinary teams, developing focused strategies, negotiating deals and raising capital in the private and public sectors. From November 2011 to November 2014 he was President, CEO and a member of the board of Ambit Biosciences, where he built and lead the team that: accelerated the development of the company’s lead drug from Phase 2 to Phase 3, completed a successful IPO in May 2013, and closed a merger with Daiichi Sankyo in November 2014. Prior to Ambit, Mike was a co-founder and CEO of Arzeda, a synthetic biology company that he helped spin-out of the University of Washington. From 1998 to 2007 Mike was President, CEO and a member of the board of Sonus Pharmaceuticals, a publicly-traded company, where he refocused the company on oncology drugs, accelerated the development of the company’s lead drug from preclinical studies to the completion of a pivotal Phase 3 study in five years, raised more than $100 million in new capital and ultimately engineered the company’s reverse merger with Oncogenex Technologies. Mike began his career with Mallinckrodt in 1983 where, over 15-years, he progressed through staff positions in planning, business development, marketing and general management, including VP & General Manager of Mallinckrodt’s global nuclear medicine business. Mike has a BBA from Roanoke College, and a MBA from Virginia Tech. He sits on the board of Arzeda, and is a prior Chair of the Board of the Washington Biotechnology & Biomedical Association (WBBA) and of the Board of Trustees of Cascadia Community College, all in Seattle.
Dale Peterson, PhD
With a talent for forming multidisciplinary teams to commercialize challenging, valuable new medical products, Dale has successfully commercialized 18 medical devices including combination and PMA products such as the first clinical cell culture system (Stericell™), the first clinical stem cell isolation system (CellPro’s CePrate™), the first automated food pathogen identification instrument (RiboPrinter™), BioFiber™ products made from a new resorbable polymer, and the first microvascular-based products. He holds 22 issued US patents in 9 disciplines. Dale has helped start-up four companies (CellPro, Intent, MicroVascular Tissues, HemaFlo Therapeutics), three successful joint ventures (Stericell, DePuy-Dupont Orthopedics, Qualicon), and experienced three IPO’s (CellPro, DePuy, Tornier). He has also worked at DuPont, Boehringer-Mannheim, J&J, Tornier, and consulted for firms in fields such as cardiovascular devices, stem cells, and tissue replacements. In addition to R&D roles, he led the Tissue Engineering initiative for Ethicon (NBD) and evaluated hundreds of businesses for the Vertical Group. He earned a BS degree in chemical engineering summa cum laude from Brigham Young University, and a PhD in chemical engineering from the University of Washington.
Sterling’s initial business career was with Eli Lilly & Company and its subsidiaries. His assignments were in sales, market research, marketing and senior executive management responsibilities in the USA, Europe and Japan. Through these experiences he established a foundation in business development, partnering and licensing in the life science industry. Subsequent employment resulted in Sterling becoming CEO and or President of four companies and a board director of others. He has special expertise in the establishment of new enterprises, business development and licensing activities on a global scale, as well as alliance management and M&A work. He founded four companies, either directly or on contract for an employer or client, and continues to establish national and global operations. It is estimated that Sterling has negotiated and executed more than 150 joint venture, M&A and license agreements in the fields of human pharmaceuticals, medical devices, drug delivery, animal health and agri-
In addition to Lilly, Sterling has been employed by, or has served as a consultant to, The Liposome Company in New Jersey, Escalon Medical Inc. in New Jersey (founded), Medtech Ltd. in Ireland, Grayson & Associates in Colorado, Biota Holdings in Australia and Biota, Inc. in California (founded), Midatech Ltd. in the UK and Midatech USA, Inc. (founded), Hovione Ltd. in Portugal, SynTara LLC in Pennsylvania (founded), MAUI Imaging Inc. in California, EyeCyte Inc. in California and most recently MonoSol Rx in New Jersey.
Kevin Ohashi, PhD
Kevin Ohashi is the Managing Partner and a co-founder of Pond Capital, LLC. He has been a co-founder of several start-up firms including Cayenne Medical, nContact, Tissue Solutions, OC2, Tauten, Microvascular Tissues, and Metis Manufacturing. Over the past fifteen years he has worked for the Vertical Group, Tornier, Bay Innovations, Corazon Technologies and the M&D Coutts Institute for Joint Reconstruction and Research. He has also consulted for a number of medical device companies in the areas of biomaterials, surgical sealants, stent technologies, and surgical instrumentation (pulmonary, vascular, ENT, orthopaedic, and cardiovascular). Kevin has helped commercialize 11 medical devices to date. He earned a BSc from the University of California, an S.M. from Harvard-MIT Division of Health, Science and Technology, an MBA from MIT Sloan School of Management and a M.S. and a Ph.D. from Stanford University.
Lael Pickett had a long career in Regulatory Affairs at 3M and Guidant, but also was responsible for regulatory work on the Taxus stent at Surmodics and then Boston Scientific. She has had a wealth of experience with regulatory agencies around the world and has gained approval of Class III (PMA) devices, combination devices, biologics in the US and EU in addition to more traditional 510(k) clearances. Since her formal retirement Lael has consulted for many companies and is an expert at persuading the FDA to accept her viewpoint.
Joseph Bonventre, MD/PhD
Dr. Bonventre holds appointments as Chief of both the Renal Division and the Founding Chief of the Biomedical Engineering Division at a large academic medical center. He runs a large, productive research lab focused on kidney injury, repair, and signal transduction and has over 300 peer-reviewed publications and 150 invited book chapters and reviews. He is past president of the American Society for Nephrology, received two MERIT awards from the NIH, and has been elected to the American Society of Clinical Investigation, the Association of American Physicians, and the American Institute for Medical and Biological Engineering. He served as director of the Harvard-MIT Health Sciences and Technology program for 10 years and was the founding head of the Kidney Group and is now on the Executive Committee of the Harvard Stem Cell Institute. He served on the Board of Directors of AMAG Pharmaceuticals and has been a Founding Board of Directors member of the National Space Biology Research Institute. He is also the co-founder of two companies and an advisor to a number of other pharmaceutical and biotechnology companies.
In addition to his BS with distinction in Engineering Physics from Cornell, Dr. Bonventre holds MD and PhD degrees in biophysics from Harvard University and honorary degrees from Mt. Saint Mary’s College and from the Norwegian Institute of Science and Technology.